HRAS and neoplasm: BRAFV600E melanoma cell lines (DMBC11, DMBC12, DMBC21, DMBC28, DMBC29 and DMBC33) derived from six different tumor specimens were used to develop resistance to vemurafenib (PLX), whereas to obtain melanoma cell lines resistant to trametinib (TRA), in addition to BRAFV600E melanoma cell lines, one Harvey rat sarcoma viral oncogene homolog (HRASQ61R) cell line (DMBC17) was employed.